You are now leaving Twirla.com/hcp
and being directed to the website for
Sterling Specialty Pharmacy

A contraceptive patch purposefully designed for her

Not actual size.

Introducing Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, the first and only combined hormonal once-weekly birth control patch delivering a low dose of estrogen.1-5

Twirla is for use in women of reproductive potential with a BMI <30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Consider Twirla’s reduced effectiveness in women with a BMI ≥25 to <30 kg/m2 before prescribing.

Not actual size.

A lower estrogen dose than other contraceptive patches

Twirla delivers 30 mcg of estrogen daily, the lowest exposure of estrogen in a transdermal contraceptive option.2-4

Transdermal Hormonal Delivery

Not actual size.
For illustrative purposes only.

Woven, flexible fabric

Twirla utilizes proprietary patch technology, designed with a woven, flexible fabric.1

Skinfusion® Technology

Not actual size.
For illustrative purposes only.

References: 1. Nelson AL, Kaunitz AM, Kroll R, et al. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results. Contraception. 2021;103(3):137-143. 2. Twirla [prescribing information]. Princeton, NJ: Agile Therapeutics, Inc.; 2020. 3. Xulane [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals; 2020. 4. Zafemy [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; 2021. 5. Centers for Disease Control and Prevention. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(3):1-104.

IMPORTANT SAFETY INFORMATION

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥30 kg/m2

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including TWIRLA, are contraindicated in women who are over 35 years of age and smoke.

Contraindicated in Women with a BMI ≥30 kg/m2

TWIRLA is contraindicated in women with a BMI ≥30 kg/m2. Compared to women with a lower BMI, women with a BMI ≥30 kg/m2 had reduced effectiveness and may have a higher risk for venous thromboembolic events (VTEs).